Radio(chemo)therapy in locally advanced nonsmall cell lung cancer

Abstract

Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable to improve outcome and minimise radiation-induced toxicity. An insight into the rationale of radiotherapy planning for stage III NSCLC is also provided. @ERSpublications Concomitant radiochemotherapy is an established standard treatment for locally advanced nonsmall cell lung cancer http://ow.ly/TTkkc

The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non–small cell lung cancer: a literature review and pooled analysis

“…A fourth study included patients treated with RT or CRT [ 24 ]. It was difficult to evaluate the endpoints of this analysis separately for the RT and the CRT cohorts, and in light of the differences in treatment outcomes between RT and CRT [ 29] , that study was also excluded. The data from the remaining three retrospective studies were evaluated in this article [ 26 – 28 ].…”

Pulmonary emphysema is a risk factor for radiation pneumonitis in NSCLC patients with squamous cell carcinoma after thoracic radiation therapy

“…Concurrent chemoradiotherapy is usually the standard treatment for patients with locally advanced NSCLC 24 . However, cases that underwent concurrent chemoradiotherapy were less than the other studies in our data.…”

HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma

“…Histologically, lung cancer is generally divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (2). NSCLC, including lung squamous cell carcinoma (LSCC) and lung adenocarcinoma (LADC), accounts for ~85% of all lung cancer cases and is the most commonly diagnosed type of lung cancer (2,3). Studies have demonstrated that LADC is overtaking LSCC as the most common histological subtype in various countries, such as the United States and China (4,5).…”